Search Results

Braeburn Inc. announces the publication of a post hoc analysis in the Journal of the American Medical Association (JAMA) Network Open.

The FDA approved Braeburn Pharmaceuticals’ new buprenorphine treatment option with extended-release medication that could pave the way for greater patient compliance.

Braeburn announces that the U.S. Food and Drug Administration (FDA) has approved BRIXADI (buprenorphine) extended-release injection for subcutaneous use (CIII), a new weekly and monthly medication for moderate to severe opioid use disorder (OUD).

ChromaDex Corp., the global authority on nicotinamide adenine dinucleotide research and its application to healthy aging, unveils Niagen+, the first-of-its-kind pharmaceutical-grade Niagen®.

The November layoffs are the second known workforce reduction this year for Marinus Pharmaceuticals, which previously announced disappointing Phase III results for ganaxolone in two clinical trials.

Altruix announced today that it has been selected as a limited distribution partner by Braeburn Inc. for BRIXADI (buprenorphine) extended-release subcutaneous injection (CIII).

Camurus AB (NASDAQ STO: CAMX) today announced that its US licensee Braeburn has resubmitted the New Drug Application (NDA) for Brixadi 1 (buprenorphine) extended-release weekly and monthly injections for the treatment of moderate to severe opioid use disorder to the US Food and Drug Administration (FDA).

Braeburn announces that today the New Drug Application (NDA) for BRIXADI was resubmitted to the U.S. Food and Drug Administration (FDA).

Braeburn announces that BRIXADI (buprenorphine) extended-release injection for subcutaneous use (CIII), a new weekly and monthly medication for moderate to severe opioid use disorder (OUD) in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine, is now available in the U.S.